Indolylarylsulfones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: New Cyclic Substituents at Indole-2-carboxamide

被引:133
作者
La Regina, Giuseppe [1 ]
Coluccia, Antonio [1 ]
Brancale, Andrea [2 ]
Piscitelli, Francesco [1 ]
Gatti, Valerio [1 ]
Maga, Giovanni [3 ]
Samuele, Alberta [3 ]
Pannecouque, Christophe [5 ]
Schols, Dominique [5 ]
Balzarini, Jan [5 ]
Novellino, Ettore [4 ]
Silvestri, Romano [1 ]
机构
[1] Univ Roma La Sapienza, Inst Pasteur, Fdn Cenci Bolognetti, Dipartimento Chim & Tecnol Farmaco, I-00185 Rome, Italy
[2] Cardiff Univ, Welsh Sch Pharm, Cardiff CF10 3NB, S Glam, Wales
[3] CNR, Ist Genet Mol, I-27100 Pavia, Italy
[4] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
[5] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
关键词
INDOLYL ARYL SULFONES; WILD-TYPE; DRUG-RESISTANCE; CRYSTAL-STRUCTURES; BINDING MODE; IN-VITRO; MUTATIONS; DISCOVERY; POTENT; DERIVATIVES;
D O I
10.1021/jm101614j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
New indolylarylsulfone derivatives bearing cyclic substituents at indole-2-carboxamide linked through a methylene/ethylene spacer were potent inhibitors of the WT HIV-1 replication in CEM and PBMC cells with inhibitory concentrations in the low nanomolar range. Against the mutant L100I and K103N RT HIV-1 strains in MT-4 cells, compounds 20, 24-26, 36, and 40 showed antiviral potency superior to that of NVP and EFV. Against these mutant strains, derivatives 20, 24-26, and 40 were equipotent to ETV. Molecular docking experiments on this novel series of IAS analogues have also suggested that the H-bond interaction between the nitrogen atom in the carboxamide chain of IAS and Glu138:B is important in the binding of these compounds. These results are in accordance with the experimental data obtained on the WT and on the mutant HIV-1 strains tested.
引用
收藏
页码:1587 / 1598
页数:12
相关论文
共 55 条
  • [1] [Anonymous], FLEXX VERS 2 2
  • [2] [Anonymous], AMBERTOOLS VERS 1 4
  • [3] [Anonymous], COD SCOR SVL WAS OBT
  • [4] [Anonymous], 2009 AIDS EPIDEMIC U
  • [5] [Anonymous], PYMOL VERS 1 2R1
  • [6] [Anonymous], MOL OP ENV MOE VERS
  • [7] ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS)
    BARRESINOUSSI, F
    CHERMANN, JC
    REY, F
    NUGEYRE, MT
    CHAMARET, S
    GRUEST, J
    DAUGUET, C
    AXLERBLIN, C
    VEZINETBRUN, F
    ROUZIOUX, C
    ROZENBAUM, W
    MONTAGNIER, L
    [J]. SCIENCE, 1983, 220 (4599) : 868 - 871
  • [8] The Amber biomolecular simulation programs
    Case, DA
    Cheatham, TE
    Darden, T
    Gohlke, H
    Luo, R
    Merz, KM
    Onufriev, A
    Simmerling, C
    Wang, B
    Woods, RJ
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) : 1668 - 1688
  • [9] Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors
    Ceccherini-Silberstein, Francesca
    Svicher, Valentina
    Sing, Tobias
    Artese, Anna
    Santoro, Maria Mercedes
    Forbici, Federica
    Bertoli, Ada
    Alcaro, Stefano
    Palamara, Guido
    Monforte, Antonella d'Arminio
    Balzarini, Jan
    Antinori, Andrea
    Lengauer, Thomas
    Perno, Carlo Federico
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (20) : 11507 - 11519
  • [10] Corbett JW, 2002, PROGR MED CHEM, V40, P63, DOI 10.1016/S0079-6468(08)70082-1